Skip to main content
Kamada Ltd. logo

Kamada Ltd. — Investor Relations & Filings

Ticker · KMDA ISIN · IL0010941198 TA Manufacturing
Open in API
Filings indexed 822 across all filing types
Latest filing 2022-03-02 Report Publication Anno…
Country IL Israel
Listing TA KMDA

About Kamada Ltd.

https://www.kamada.com

Kamada Ltd. is a vertically integrated global biopharmaceutical company specializing in plasma-derived protein therapeutics. The company develops, manufactures, and commercializes a portfolio of products for rare and serious conditions, with a focus on therapeutic areas such as Alpha-1 Antitrypsin Deficiency (AATD) and Cytomegalovirus (CMV) prevention in transplant patients. Kamada utilizes a proprietary platform technology for advanced protein extraction and purification from human plasma. In addition to its marketed products, the company maintains a development pipeline of new therapies, including an inhaled treatment for AATD.

Recent filings

Filing Released Lang Actions
Kamada to Announce Fourth Quarter and Fiscal Year Ended December 31, 2021 Financial Results, and Host Conference Call on March 15, 2022
Report Publication Announcement Classification · 1% confidence The document is an 'Immediate Report' filed with the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE). The title explicitly states: 'Kamada to Announce Fourth Quarter and Fiscal Year Ended December 31, 2021 Financial Results, and Host Conference Call on March 15, 2022'. Crucially, the text includes the line: 'Attached hereto is a report on... *ea156403-6k_kamadaltdEDGAR2_bannerless_isa.pdf*'. This structure—a brief announcement stating that a financial report (likely an earnings report or annual filing) is attached or published, rather than containing the full report itself—fits the definition of a Report Publication Announcement (RPA). The document length (1991 chars) also supports this being an announcement rather than the full financial statement or earnings release.
2022-03-02 English
Results of the 2021 Annual General Meeting of Shareholders held on December 16, 2021
AGM Information Classification · 1% confidence The document is explicitly identified as a "FORM 6-K" (Report of Foreign Private Issuer) filed with the SEC for December 2021. The key exhibit attached (Exhibit 99.1) is titled "Notice of Results of the 2021 Annual General Meeting of Shareholders held on December 16, 2021." This exhibit details the proposals voted on and the results of the Annual General Meeting (AGM), specifically confirming the election of directors and ratification of auditors. Since the core content is the official results of the AGM, the most specific classification is AGM Information (AGM-R), which covers presentations and materials shared during the AGM, and the results announcement is a primary component of AGM materials. Although it is filed as a 6-K, the subject matter dictates the classification.
2021-12-16 English
Results of the 2021 Annual General Meeting of Shareholders held on December 16, 2021
AGM Information Classification · 1% confidence The document explicitly states 'Notice of Results of the 2021 Annual General Meeting of Shareholders held on December 16, 2021'. This directly relates to the outcomes of an AGM. The definition for AGM Information (AGM-R) covers 'Presentations and materials shared during the Annual General Meeting (AGM)'. Although it mentions 'Notice of Results', which could sometimes align with DVA (Declaration of Voting Results), the context of providing the notice/results *of* the AGM strongly points towards AGM-R as the primary category for AGM-related documentation, especially when it's a formal notice following the event. Given the content is the notice of the results of the AGM, AGM-R is the most appropriate classification.
2021-12-16 English
Kamada Announces Strategic Transformational Transaction Positioning the Company as a Global Leader in the Plasma-Derived Hyperimmune Market Through the Acquisition of a Portfolio of Four FDA-Approve
Regulatory Filings Classification · 1% confidence The document is explicitly titled "FORM 6-K" and is filed by a "Foreign Private Issuer" with the SEC. Form 6-K is used to report material information that a foreign private issuer is required to disclose to its home country's securities regulator or stock exchange, or that it makes public in its home country. This filing is not one of the specifically defined US periodic reports (like 10-K or IR). The content details a major corporate action: the acquisition of a product portfolio from Saol Therapeutics, including financial details and an Asset Purchase Agreement exhibit. Since this is a material event disclosure by a foreign issuer that doesn't fit the specific categories like M&A (TAR) or Capital Change (CAP) which usually refer to US domestic filings or specific transaction types, and it is a formal regulatory filing, the most appropriate general category for miscellaneous, material foreign regulatory disclosures is 'Regulatory Filings' (RNS), as it serves as the catch-all for SEC filings that aren't the primary US forms listed.
2021-11-22 English
Kamada Announces Strategic Transformational Transaction Positioning the Company as a Global Leader in the Plasma-Derived Hyperimmune Market Through the Acquisition of a Portfolio of Four FDA-Approve
Report Publication Announcement Classification · 1% confidence The document is a short filing (2090 characters) issued by KAMADA LTD, referencing the Israel Securities Authority and the Tel Aviv Stock Exchange. It is labeled as an 'Immediate Report' under Regulation 4 for a Foreign Corporation. Crucially, the text states: 'Attached hereto is a report on *Kamada Announces Strategic Transformational Transaction...* ea151143-6k_kamadaltdEDGAR4_Bannerless_isa.pdf'. This structure—a brief announcement stating that a substantive report is attached or referenced, rather than containing the full report content itself—fits the definition of a Report Publication Announcement (RPA). It is announcing the publication of a transaction/M&A related document, but the filing itself is the announcement mechanism.
2021-11-22 English
Kamada Reports Third Quarter and First Nine Months of 2021 Financial Results, and Strategic Transformational Acquisition of a Portfolio of Four FDA-Approved Plasma-Derived Hyperimmune Commercial Prod
Earnings Release Classification · 1% confidence The document is explicitly titled 'FORM 6-K' and is filed 'For the Month of November 2021' by a 'Foreign Private Issuer'. Form 6-K is a periodic report required by the SEC for foreign private issuers, often used to file material information that is otherwise required to be disclosed in the home country or to shareholders. The content includes financial highlights for the third quarter and first nine months of 2021, and an announcement of a major acquisition. This structure—a mandatory SEC filing containing earnings information and significant corporate updates—most closely aligns with the purpose of an Interim/Quarterly Report (IR) or a general Regulatory Filing (RNS). Since Form 6-K is a comprehensive filing that includes detailed financial results (Exhibit 99.2 contains 'Consolidated Financial Statements as of September 30, 2021 (Unaudited)') and management discussion (Exhibit 99.1 is the press release detailing Q3 results), it functions as a comprehensive quarterly disclosure. Given the options, 'Interim / Quarterly Report' (IR) is the most appropriate classification for a filing that contains the full quarterly financial statements and management discussion, even though the SEC form itself is 6-K. It is not merely an Earnings Release (ER) as it contains full statements, nor is it a 10-K (Annual Report). It is a comprehensive report for a period shorter than a year. 9M 2021
2021-11-22 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.